Bank of America Upgrades Optimer Pharmaceuticals To Buy, PT To $17

April 4, 2011 8:41 AM | 8 seconds read |
Bank of America has upgraded Optimer Pharmaceuticals OPTR from Neutral to Buy and has raised the price target from $14 to $17.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: UpgradesPrice TargetAnalyst RatingsBank of AmericaHealth Careoptimer pharmaceuticalsPharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!